Strategic acquisitions Certara’s integration of Analytica Laser and BaseCase signals a broadened capability in value assessment and communication. This presents cross-sale opportunities to clients seeking end-to-end analytics, population health insights, and cloud-based value messaging within one integrated platform.

AI and data leverage Recent partnerships with NVIDIA and the launch of a Python API indicate a strong move toward AI-enabled modeling and data interoperability. Sales teams can position Certara as a provider of AI-first, integrated scientific platforms to accelerate drug development and real-world evidence generation.

Regulatory and medical write Certara plans to divest or has divested Regulatory and Medical Writing assets to Veristat, signaling a strategic refocus. This creates opportunities to upsell remaining regulatory analytics, evidence generation, and value communication services to clients needing streamlined regulatory support.

Key client expansion New engagement with Gilead Sciences for high-quality real-world evidence on remdesivir demonstrates appetite among top pharma players for evidence generation. Target similarly sized biopharma and specialty companies pursuing RWE, value communication, and regulatory strategy capabilities.

Public market signals Transient CFO transition and publicly reported revenue near the million-dollar mark, combined with a multi-location global footprint, suggest an evolving growth phase. Position Certara as a scalable partner for mid-market to large pharma transitioning to cloud-based analytics, AI-enabled modeling, and global evidence strategies.